We now have ten separate members of the extended IL-1 family [IL-1Fx] identified including IL-18 as the most distantly related member. The biologic role of many of these cytokines is unclear but IL-1alpha/IL-1F1, IL-1beta/IL-1F2, IL-18/IL-1F4, and IL-1H4/IL-1F7 promote antitumor responses when used as genetic constructs. We have previously shown in vitro that the antitumor effects of rIL-18 delivered in murine tumor models can be mimicked with coculture of murine DCs, NK cells, tumor, T-cells and IL-18, leading to the generation of tumor specific T-cells. IL-18 gene therapy is dependent on DC and NK cells, Fas signaling but not on NKT cells nor IFNgamma nor IL-12. A novel IL-1 homologue, IL-1H4/IL-1F7 also mediates antitumor effects, which are IL-12-dependent and Fas dependent, demonstrating a mixture of biologic effects attributable to IL-12 and IL-18. We will now explore these cytokines in human in vitro studies with DC and NK cells interacting to promote a T-cell response to human melanoma. We will thus explore whether the other IL-1 homologues including IL-1alpha, IL-1beta, IL1RA, IL-1F5/IL-1F9 and IL-1H4 [IL-1F7] mediate similar or dissimilar effects in in vitro culture. We will evaluate the critical components of the coculture system in human in vitro cultures with human melanoma. We will also evaluate whether IL-12 production is enhanced in an IFNgamma dependent manner in such cultures generating successful development of specific T-cells in NK and DC cultured with tumor. We will contrast the role of the IL-1 family members in cooperation with Project I to assess similar readouts in murine melanoma and the relative contributory roles of the TNF family members and the extended IL-12 family members with Project II. An important question will be to test these premises in vivo in patients with melanoma and we will assess this in innovative clinical protocols assessing local tumor response in patients with multiple cutaneous melanoma metastases and contrast with ex vivo strategies in patients with melanoma in Project II. We will test these notions in the following Specific Aims:
Aim 1. Evaluate IL-1 homologues and their ability to promote NK and DC activation, polarization;
Aim 2. Develop specific T-cell reactivity to autologous and MHC matched melanoma in vitro with IL-1 homologues;
Aim 3. Integrate NK and DC biomarkers with IL-1 homologues and proteomic assays in treated melanoma patients and Aim 4. Administer ANK/DC to melanoma patients in sequential clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA101944-03
Application #
7560577
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
3
Fiscal Year
2007
Total Cost
$562,884
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Radomski, Michal; Zeh, Herbert J; Edington, Howard D et al. (2016) Prolonged intralymphatic delivery of dendritic cells through implantable lymphatic ports in patients with advanced cancer. J Immunother Cancer 4:24
Kang, R; Tang, D; Schapiro, N E et al. (2014) The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics. Oncogene 33:567-77
Kaufmann, Stefan H E; Lange, Christoph; Rao, Martin et al. (2014) Progress in tuberculosis vaccine development and host-directed therapies--a state of the art review. Lancet Respir Med 2:301-20
Wong, Jeffrey L; Berk, Erik; Edwards, Robert P et al. (2013) IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment. Cancer Res 73:4653-62
Wong, Jeffrey L; Muthuswamy, Ravikumar; Bartlett, David L et al. (2013) IL-18-based combinatorial adjuvants promote the intranodal production of CCL19 by NK cells and dendritic cells of cancer patients. Oncoimmunology 2:e26245
Vernon, Philip J; Loux, Tara J; Schapiro, Nicole E et al. (2013) The receptor for advanced glycation end products promotes pancreatic carcinogenesis and accumulation of myeloid-derived suppressor cells. J Immunol 190:1372-9
Kang, Rui; Tang, Daolin; Lotze, Michael T et al. (2013) Autophagy is required for IL-2-mediated fibroblast growth. Exp Cell Res 319:556-65
Livesey, Kristen M; Kang, Rui; Zeh 3rd, Herbert J et al. (2012) Direct molecular interactions between HMGB1 and TP53 in colorectal cancer. Autophagy 8:846-8
Liang, Xiaoyan; De Vera, Michael E; Buchser, William J et al. (2012) Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression. Cancer Res 72:2791-801
Livesey, Kristen M; Kang, Rui; Vernon, Philip et al. (2012) p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res 72:1996-2005

Showing the most recent 10 out of 65 publications